- Home
- IHD vs COEP Comparison
IHD vs COEP Comparison
Compare IHD & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IHD | COEP |
|---|---|---|
| Founded | 2011 | 2017 |
| Country | United States | United States |
| Employees | N/A | 7 |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.5M | 72.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | IHD | COEP |
|---|---|---|
| Price | $6.58 | $12.15 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 157.5K | 33.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 10.32% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.54 | $6.32 |
| 52 Week High | $7.28 | $21.41 |
Technical Indicators
Market Signals| Indicator | IHD | COEP |
|---|---|---|
| Relative Strength Index (RSI) | 43.08 | 45.04 |
| Support Level | $5.82 | $11.76 |
| Resistance Level | $7.19 | $13.23 |
| Average True Range (ATR) | 0.15 | 0.90 |
| MACD | -0.05 | 0.05 |
| Stochastic Oscillator | 31.72 | 38.21 |
Price Performance
Historical ComparisonAbout IHD Voya Emerging Markets High Income Dividend Equity Fund
Voya Emerging Markets High Dividend Equity Fund is a diversified closed-end management investment company. Its primary investment objective is to provide total return through a combination of current income, capital gains, and capital appreciation. The company seeks to achieve its investment objectives by investing principally in a portfolio of equity securities, and issuers in emerging market countries. The Fund will also normally seek to secure gains and enhance the stability of returns over a market cycle by writing (selling) call options on selected exchange-traded funds (ETFs) and/or international, regional, or country indices of equity securities, and/or on equity securities.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.